Abraham Ludomirski, Director at Recro Pharma, Inc. (REPH), sold 92,042 shares at $9.00 ($701K) on 2015-11-23, disclosed to the SEC on 2016-05-23.
Open-market sale of $701k REPH by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $9.00 | 3,702 | $33K | 4.8% |
| 2 | $9.00 | 3,702 | $33K | 4.8% |
| 3 | $9.00 | 11,082 | $100K | 14.2% |
| 4 | $9.01 | 2,068 | $19K | 2.7% |
| 5 | $9.01 | 691 | $6K | 0.9% |
| 6 | $9.01 | 691 |
| $6K |
| 0.9% |
| 7 | $9.01 | 2,068 | $19K | 2.7% |
| 8 | $9.00 | 1,553 | $14K | 2.0% |
| 9 | $9.00 | 4,648 | $42K | 6.0% |
| 10 | $9.00 | 2,250 | $20K | 2.9% |
| 11 | $9.00 | 6,737 | $61K | 8.6% |
| 12 | $9.00 | 2,250 | $20K | 2.9% |
| 13 | $9.00 | 150 | $1K | 0.2% |
| 14 | $9.00 | 450 | $4K | 0.6% |
| 15 | $6.46 | 3,748 | $24K | 3.5% |
| 16 | $6.46 | 1,252 | $8K | 1.2% |
| 17 | $6.46 | 3,748 | $24K | 3.5% |
| 18 | $6.46 | 1,252 | $8K | 1.2% |
| 19 | $6.45 | 5,008 | $32K | 4.6% |
| 20 | $6.45 | 14,992 | $97K | 13.8% |
| 21 | $6.45 | 5,008 | $32K | 4.6% |
| 22 | $6.45 | 14,992 | $97K | 13.8% |
| Total | $7.62 avg | 92,042 | $701K | 100% |
| Filing → |
| RWLK | SELL | 2016-06-06 | $194K | — | Filing → |